EP Biocomposites PAT rises 41.5% on revenue growth in FY26
EP Biocomposites Limited reported a 41.5% increase in net profit to ₹145.83 lakh for FY26, driven by a 13.6% rise in revenue to ₹1,363.98 lakh and improved operational efficiency. EBITDA grew 26.23% to ₹237.83 lakh with margins expanding to 17.44%, while net worth crossed ₹12 crore and ROCE improved to 16%. The company successfully utilized IPO proceeds for capacity expansion and debt repayment, strengthening its balance sheet with total assets rising to ₹1,873.14 lakh.

*this image is generated using AI for illustrative purposes only.
EP Biocomposites Limited reported a 41.5% increase in net profit to ₹145.83 lakh for the financial year ended March 31, 2026, driven by a 13.6% rise in revenue and improved operational efficiency. Revenue from operations grew to ₹1,363.98 lakh from ₹1,200.62 lakh in the previous year. The board of directors approved the audited financial statements for the year at a meeting held on May 26, 2026.
The company’s EBITDA for FY26 stood at ₹237.83 lakh, a 26.23% increase from ₹188.41 lakh in FY25, with margins expanding to 17.44%. Profit before tax improved to ₹193.73 lakh from ₹141.70 lakh in the same period. Earnings per share (EPS) increased to ₹8.67 from ₹6.13 in the previous year. The statutory auditors carried out the audit of the financial statements, confirming compliance with applicable accounting standards.
Financial Performance
The following table outlines the key financial metrics for EP Biocomposites Limited for the year ended March 31, 2026:
| Metric | FY26 (₹ in Lakhs) | FY25 (₹ in Lakhs) |
|---|---|---|
| Revenue from Operations | 1,363.98 | 1,200.62 |
| Total Income | 1,378.10 | 1,211.50 |
| Total Expenses | 1,184.37 | 1,069.80 |
| EBITDA | 237.83 | 188.41 |
| Profit Before Tax | 193.73 | 141.70 |
| Net Profit | 145.83 | 103.08 |
| Earnings Per Share (Basic) | 8.67 | 6.13 |
Operational Highlights
Net worth crossed ₹12 crore as of March 31, 2026, reflecting continued financial strengthening. Return on Investment (ROI) stood at 14%, while Return on Capital Employed (ROCE) improved to 16% during FY26. The company successfully utilized IPO proceeds towards capacity expansion, working capital, and business growth initiatives, strengthening the balance sheet through partial debt repayment and improved liquidity.
Balance Sheet Highlights
The company’s balance sheet strengthened with total assets increasing to ₹1,873.14 lakh as of March 31, 2026, compared to ₹1,662.66 lakh a year ago. Shareholders' funds rose to ₹1,205.30 lakh from ₹1,059.48 lakh, supported by reserves and surplus which grew to ₹1,037.15 lakh. Cash and cash equivalents improved significantly to ₹215.35 lakh from ₹161.67 lakh, indicating robust liquidity.
Historical Stock Returns for EP Biocomposites
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.79% | +1.79% | +25.34% | +9.80% | -9.26% | -37.38% |
How does EP Biocomposites plan to sustain the 26.23% EBITDA growth margin in the face of potential raw material price volatility?
What specific new markets or product lines is the company targeting with the recently completed capacity expansion?
Will the company consider declaring dividends in the upcoming fiscal year given the robust cash reserves and improved liquidity?





























